SCHEMBL3740513

SCHEMBL3740513

O=C(/C=C/c1cccc(Cl)n1)c1ccc(C(F)(F)F)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 5/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
MAOB P27338 3/20 0.39
MAOA P21397 1/20 0.39
PFKFB3 Q16875 2/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
GAA P10253 1/20 0.36
P4HB P07237 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3746164 0.85 PFKFB3 (0.41) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3734671 0.82 CYP1A1 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3743383 0.78 MAOB (0.64) MAOBMAOACYP1A1CYP1B1P4HB
SCHEMBL3740611 0.77 CYP1B1 (0.55) NFE2L2HDAC3HDAC4HDAC1HDAC7
SCHEMBL3740516 0.76 P4HB (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3738224 0.71 PTGS2 (0.50) MAOBMAOACYP1A1CYP1B1
SCHEMBL3743387 0.71 CYP1A1 (0.60) HDAC4HDAC1MAOBMAOACYP1A1
SCHEMBL3735485 0.71 MAOB (0.51) MAOBMAOACYP1A1CYP1B1P4HB
SCHEMBL3729435 0.70 MAOB (0.47) MAOBMAOACYP1A1CYP1B1P4HB
SCHEMBL3734079 0.69 CYP1A1 (0.47) MAOBMAOACYP1A1CYP1B1P4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114867-B1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
EP-2114867-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
WO-2008107335-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-12 WO disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HCRTR1, HCRTR2, HRH3 NFE2L2 1367/4885HDAC3 449/4885HDAC4 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.